Kevin McKernan is a notable figure in genomics, particularly for his contributions to the Human Genome Project. His work advanced the understanding of genetic information.
The Human Genome Project’s Vision
The Human Genome Project (HGP) was an international scientific research endeavor launched in 1990. Its overarching goal was to map and sequence the entire human genome, determining the precise order of its approximately 3 billion base pairs and identifying all human genes.
The HGP involved developing advanced DNA sequencing technologies and tools for data analysis. This massive collaborative effort, led by a public consortium including MIT’s Eric Lander, involved researchers from over 40 institutions globally. The project openly shared generated data, making it accessible to scientists worldwide for further research.
McKernan’s Pioneering Approach
Kevin McKernan’s contributions focused on developing and advocating for open-source sequencing technologies. He managed research and development for the Human Genome Project at the Whitehead Institute/MIT Center for Genome Research, gaining foundational insights into large-scale genomic sequencing.
In 2000, he co-founded Agencourt Biosciences Corporation, serving as Chief Scientific Officer, which was later acquired by Beckman Coulter. He then co-founded Agencourt Personal Genomics in 2005. This startup aimed to drastically reduce the cost of sequencing a human genome from an initial $300 million to approximately $3,000.
McKernan was instrumental in the early adoption and development of next-generation sequencing (NGS) methods. As Vice President and Director of R&D, he managed the development of Life Technologies’ SOLiD sequencing technology. He was also involved in the acquisition of Ion Torrent, a company specializing in DNA sequencing.
McKernan’s philosophical stance emphasized accessibility and cost-efficiency in genomic sequencing. He advocated for open data sharing to democratize genomic research. After leaving Ion Torrent, he founded Medicinal Genomics Corporation in 2011, publicly releasing the first genome sequence for Cannabis sativa L. This exemplified his commitment to open science.
Influence on Genomics
Kevin McKernan’s work significantly impacted genomics by making sequencing technology more accessible. His efforts in developing and promoting next-generation sequencing methods, particularly through companies like Agencourt Personal Genomics and his work on the SOLiD platform, led to a significant reduction in sequencing costs and increased speed. This shift from high-cost, centralized sequencing to more affordable, distributed approaches allowed a broader range of researchers to engage in genomic studies.
His advocacy for open science and data sharing fostered a more collaborative scientific community. This approach encourages rapid dissemination of information, accelerating discovery and application of genomic insights.
McKernan’s focus on cost reduction and accessibility has democratized genomics. This enabled smaller laboratories and individual researchers to undertake projects previously limited to large institutions. The widespread adoption of these efficient sequencing methods has broadened genomic research, influencing fields from human health to agricultural applications.